FDA Clears AI Assessment of Ischemic Core Volume on CT with Brainomix 360 Platform
For patients with acute ischemic stroke, research has demonstrated that automated assessment of ischemic core volume on brain CT scans via the Brainomix 360 software is equivalent to that derived from CT perfusion.
The Food and Drug Administration (FDA) has granted 510(k) clearance for artificial intelligence (AI)-enabled assessment of ischemic core volume on non-contrast computed tomography (CT) scans with Brainomix 360 software.1
Brainomix, the developer of the software, said the ischemic core volume feature with the Brainomix 360 platform is a “critical advancement in stroke imaging” that facilitates timely evaluation, triage, and treatment.1
Recently published research has demonstrated similar ischemic core volumes between Brainomix 360 assessment and CT perfusion (20.4 mL vs. 19.9 mL) in patients with acute ischemic stroke.2
“The ability of Brainomix 360 to estimate ischemic core volumes in a reliable and reproducible manner with a similar performance to CT perfusion represents an attractive alternative in centers without ready access to either advanced imaging modalities or stroke neurologist and/or neuroradiologist for imaging interpretation and has the potential to make endovascular therapy more widely available,” noted Mehdi Bouslama, M.D., an attending physician in neuroendovascular surgery and vascular neurology with Broward Health in South Florida.
References
1. Brainomix. Brainomix advances stroke care with landmark FDA clearance. PR Newswire. Available at: https://www.prnewswire.com/news-releases/brainomix-advances-stroke-care-with-landmark-fda-clearance-302421952.html . Published April 8, 2025. Accessed April 8, 2025.
2. Shahrouki P, Kihira S, Tavaakol E, et al. Automated assessment of ischemic core on non-contrast computed tomography: a multicenter comparative analysis with CT perfusion. J Neurointerv Surg. 2024;16(12):1288-1293.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
